Carmell Therapeutics Corp...

0.20
0.01 (2.77%)
At close: Mar 07, 2025, 3:55 PM
2.77%
Bid 0.2
Market Cap 5.94M
Revenue (ttm) -5.33M
Net Income (ttm) -11.28M
EPS (ttm) 0.48
PE Ratio (ttm) 0.41
Forward PE n/a
Analyst n/a
Ask 0.21
Volume 63,382
Avg. Volume (20D) 8,229,021
Open 0.20
Previous Close 0.19
Day's Range 0.19 - 0.21
52-Week Range 0.17 - 3.00
Beta 0.51

About CTCX

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was foun...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 23, 2021
Employees 9
Stock Exchange NASDAQ
Ticker Symbol CTCX
Full Company Profile
3 months ago
+147.98%
Carmell Therapeutics shares are trading higher aft... Unlock content with Pro Subscription
3 months ago
+26.2%
Carmell shares are trading higher after the announced it has entered securities purchase agreement with new and existing investors.